Passage Bio (PASG) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Passage Bio (PASG) is Neutral.

The composite score behind that read is -0.18, weighing +0.17 of bullish evidence against -0.42 bearish.

Passage Bio last closed at $3.69, -2.38% on the session.

Against the IVW growth benchmark the position is -3.18% over the forecast window.

The read is built from 15 underlying insights — 3 bullish and 12 bearish.

Agreement across those insights is 80%.

20 graded predictions for PASG so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Passage Bio in the 5th percentile on return on equity, where 100 is best.

Passage Bio is classified under Health Care / Biotechnology, with a market capitalisation of $12.16M.

StockMap tracks Passage Bio as the 350th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Passage Bio ranks 309th of 381 in the group, against a group median of -0.08.